Immutep Completes A$6.31 Million Share Purchase Plan; Raises Total of A$13.16 Million
April 12 2018 - 9:24PM
Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“
Immutep”
or the “
Company”) advises that its Share Purchase
Plan (“SPP”) closed as planned on 6 April 2018. The Company
received applications from eligible shareholders for 300,561,089
new ordinary shares (“New Shares”) at the purchase price of $0.021
per New Share.
Accordingly, the Company has raised A$6.31 million before
transaction-related expenses through the SPP. This is in addition
to A$6.85 million institutional placement announced on 12 March
2018, bringing the total funds raised from the SPP and
institutional placement to A$ 13.16 million.
The funds raised from the SPP and Placement will be used to
support Immutep’s ongoing and planned immuno-oncology clinical
development programs, its pre-clinical program in autoimmune
disease and for general working capital purposes.
“It is great to see so many of our shareholders participate in
the Share Purchase Plan, on the same terms as the Placement to
Platinum, Australian Ethical and other investors,” said Immutep
CEO, Marc Voigt. “I would like to thank our shareholders for their
continued support, especially those that have been invested in our
Company for some time.”
“This funding provides us with cash reach well into Q4 of
calendar year 2019, including funding our new Phase II TACTI-002
clinical trial in different cancer indications in collaboration
with MSD. Importantly, by that stage we will have Progression Free
Survival data from our Phase IIb AIPAC breast cancer trial, data
from all four patient cohorts in our Phase I TACTI-mel trial and
potentially also the first data from TACTI-002.”
The Company will issue the New Shares today and holding
statements will also be sent today to shareholders advising them of
the number of New Shares they have been allotted. The New Shares
are expected to commence trading on the Australian Securities
Exchange on 16 April 2018 and will rank pari passu with the
Company's existing fully paid ordinary shares on issue.
For further information please visit www.immutep.com or
contact:
U.S. Investors:Jay Campbell, Vice President of Business
Development and Investor Relations, Immutep+1 (917) 860-9404;
jay.campbell@immutep.com
Australian Investors/Media:Matthew Gregorowski,
Citadel-MAGNUS+61 (2) 8234 0100;
mgregorowski@citadelmagnus.com
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Jul 2023 to Jul 2024